Search results
Results From The WOW.Com Content Network
n/a n/a Ensembl n/a n/a UniProt n a n/a RefSeq (mRNA) n/a n/a RefSeq (protein) n/a n/a Location (UCSC) n/a n/a PubMed search n/a n/a Wikidata View/Edit Human Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n, - r ə -, - p ɔɪ ˈ ɛ t ɪ n, - ˈ iː t ɪ n / ; EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys ...
There is no general obligation for a party to be represented by a professional representative to act in proceedings before the EPO. However, a person not having either their residence or place of business within the territory of one of the EPC Contracting States (a "non-European party") "must be represented by a professional representative and act through him in all proceedings", except for ...
epoline [1] is a set of web-based computer programs and services enabling applicants, patentees and their representatives to file patent applications online before the European Patent Office (EPO), as well as to monitor the status of patent applications during their prosecution and patents during an opposition.
According to Board of Appeal 3.3.08, the observations have to be signed "in order to allow an identification of the third party" and, unless "adopted by a party to the proceedings as its own" or by the competent organ of the EPO of its own motion, "anonymous third party observations are to be disregarded altogether." [77]
As of January 1, 2016, a written, online request ("PACE request") must be filed, using a "dedicated request form (EPO Form 1005)", to request acceleration under the PACE programme. [101] The PACE requests are excluded from public inspection. [101] As of 2009, accelerated processing under PACE was reported to be requested in only 6.3% of files ...
Epoetin alfa, sold under the brand name Epogen among others, is a human erythropoietin produced in cell culture using recombinant DNA technology. [8] [9] Epoetin alfa is an erythropoiesis-stimulating agent. [8]
Article 83 of the European Patent Convention (EPC) [1] relates to the disclosure of the invention under the European Patent Convention.This legal provision prescribes that a European patent application must disclose the invention (which is the subject of the European patent application) in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art.
T 641/00, also known as Two identities/COMVIK, is a decision of a Technical Board of Appeal of the European Patent Office (EPO), issued on September 26, 2002. It is a landmark decision regarding the patentable subject matter requirement [1] and inventive step [2] under the European Patent Convention (EPC).